These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 2442806)

  • 1. Systemic therapy of metastatic renal cell carcinoma.
    Vugrin D
    Semin Nephrol; 1987 Jun; 7(2):152-62. PubMed ID: 2442806
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunotherapy for metastatic renal cell carcinoma.
    Wirth MP
    Urol Clin North Am; 1993 May; 20(2):283-95. PubMed ID: 7684167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma.
    Little B; Young M; Ho KJ
    Int J Clin Pract; 2002; 56(1):36-9. PubMed ID: 11831831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic renal cell carcinoma: systemic treatment.
    Abi-Aad AS; deKernion JB
    Acta Urol Belg; 1996 May; 64(2):3-8. PubMed ID: 8701805
    [No Abstract]   [Full Text] [Related]  

  • 5. [Immunology in clinical practice. XVII. Immunotherapy of metastatic renal cell carcinoma. Work Group Immunotherapy, Dutch Oncology].
    van Herpen CM; de Mulder PH
    Ned Tijdschr Geneeskd; 1998 Nov; 142(48):2613-8. PubMed ID: 10028361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Systemic treatment of renal-cell carcinoma--present status].
    Steiner T; Schubert J
    Dtsch Med Wochenschr; 2001 Sep; 126(39):1080-4. PubMed ID: 11602916
    [No Abstract]   [Full Text] [Related]  

  • 7. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic options in renal cell carcinoma.
    Buzaid AC; Todd MB
    Semin Oncol; 1989 Feb; 16(1 Suppl 1):12-9. PubMed ID: 2465574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The immunotherapy of advanced renal cell carcinoma].
    Bergmann L; Weidmann E; Mitrou PS
    Dtsch Med Wochenschr; 1991 Mar; 116(10):384-90. PubMed ID: 1705879
    [No Abstract]   [Full Text] [Related]  

  • 10. [Immunotherapy of metastatic renal cell cancer].
    Manseck A; Wirth M
    Urologe A; 1993 Sep; 32(5):360-73. PubMed ID: 7692655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
    Figlin RA; Pierce WC; Belldegrun A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686
    [No Abstract]   [Full Text] [Related]  

  • 13. Biological therapy for metastatic renal cell cancer.
    Lancet; 1991 Mar; 337(8740):522-3. PubMed ID: 1705643
    [No Abstract]   [Full Text] [Related]  

  • 14. [Has interleukin 2 modified the outcome of metastatic kidney cancer?].
    Négrier S; Philip T
    Ann Urol (Paris); 1993; 27(2):87-9. PubMed ID: 8503657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma.
    Pierce WC; Belldegrun A; Figlin RA
    Semin Oncol; 1995 Feb; 22(1):74-80. PubMed ID: 7855622
    [No Abstract]   [Full Text] [Related]  

  • 16. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
    Ryan CW; Vogelzang NJ; Dumas MC; Kuzel T; Stadler WM
    Cancer; 2000 Mar; 88(6):1317-24. PubMed ID: 10717612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for metastatic renal cell carcinoma.
    McDermott DF; Rini BI
    BJU Int; 2007 May; 99(5 Pt B):1282-8. PubMed ID: 17441925
    [No Abstract]   [Full Text] [Related]  

  • 18. Surveillance as a possible option for management of metastatic renal cell carcinoma.
    Oliver RT
    Semin Urol; 1989 Aug; 7(3):149-52. PubMed ID: 2602721
    [No Abstract]   [Full Text] [Related]  

  • 19. What's new in the treatment of metastatic kidney cancer?
    Mancuso A; Sternberg CN
    BJU Int; 2005 Jun; 95(9):1171-80. PubMed ID: 15892796
    [No Abstract]   [Full Text] [Related]  

  • 20. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
    Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M
    J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.